Cellaïon
We Care for the Liver,
We Care for
Lives
Cell Signaling Technology
for Liver Repair
& Organ Regeneration
Vision
Cellaïon is a Belgian biotechnology company developing life-saving advanced therapies that aim to repair tissues and regenerate organs, particularly the liver. Cellaïon targets life-threatening diseases.
Mission
We, at Cellaïon, are developing HepaStem® with an aim to restore the human body’s regenerative process and to support the survival of a failing native liver

What we do
We aim to repair tissues and regenerate organs using cell signaling technology
Our prime target is the liver space. The liver is a critical organ of the body that is responsible for an array of functions. Any downfall of its functioning leads to failure of other vital organs and ultimately death.
With HepaStem®, Cellaïon aims to stop the progression of chronic liver disease, control inflammation, stop fibrous tissue accumulation in the liver and eventually allow recovery and regeneration of the liver.
Personnal interest
Do you want to know more about us or our last research?
Interested to learn more about Cellaïon?
Health professional
Do you want to know more about us or our clinical trials? Interested to learn more about Cellaïon, HepaStem® and ongoing trials?
Pipeline
Clinical Trial / Publication
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
Published in April 2021 in JHEP Liver

Latest news
Explore our selection of research articles and news

Cellaïon News
Cellaïon SA appoints new Chief Executive Officer to drive Clinical & Commercial development

Cellaïon News
Cellaïon SA announces an additional closing of 5,5M Euros financing on June 13th 2023.

Cellaïon News
Cellaïon SA announces the arrival of Walid Abi-Saab in its Board of Directors, the hiring of Griet Goddemaer to lead clinical development and the green light from the DSMB for the continuation of ACLF- Dheliver Clinical trial.
Investors










